In vivo switching of human melanoma cells between proliferative and invasive states.

By K. Hoek, Ossia M. Eichhoff, N. Schlegel, U. Döbbeling, N. Kobert, Leo Schaerer, S. Hemmi, R. Dummer. Cancer Research, 2008

743 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Toward Minimal Residual Disease-Directed Therapy in Melanoma. (2018, methodology): “The MITFlow/SOX10low/AXLhigh-invasive subpopulation has been extensively described (Hoek et al., 2006, 2008).”
The therapeutic promise of the cancer stem cell concept. (2010, background): “murine xenotransplantation models (101, 102) and by melanomas of metastatic tumor origin, but not those that are primary tumors (103).”
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq (2016, neutral): “Notably, the “AXL-high” program has been linked to intrinsic resistance to RAF/MEK inhibition (25, 30, 31).”
An Integrated Approach to Uncover Drivers of Cancer (2010, methodology): “For example, TBC1D16 and RAB27A were both identiﬁed as transcriptional targets of MITF (Chiaverini et al., 2008; Hoek et al., 2008b) and are therefore upregulated when MITF is overexpressed.”
PGC1α Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress (2013, positive): “MITF expression was higher in melanoma samples with the proliferative signature and lower in samples with an invasive signature (Hoek et al., 2008).”
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma (2016, neutral): “, 2015), and v) melanoma invasive/proliferative signatures (Hoek et al., 2008).”